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The Rel/NF-κB family of transcription factors 
comprise critical regulators of infl  ammation, 
proliferation, and apoptosis and, collectively, 
lie at the center of both innate and adaptive 
  immune responses (1, 2). Recent eff  orts have 
identifi  ed two separate NF-κB signaling path-
ways that lead to the activation of specifi  c and 
distinct Rel dimers. In unstimulated cells,   NF-
κB dimers are sequestered in the cytoplasm by 
one of a family of inhibitory molecules, termed 
inhibitors of κB (IκBs) (3). The canonical path-
way requires activation of the trimeric IκB ki-
nase (IKK) complex (IKKα, IKKβ, and IKKγ/ 
NF-κB essential modulator), which mediates 
phosphorylation and degradation of IκBα and 
IκBβ and the release of p50:RelA and p50:
cRel dimers (3). The noncanonical or “alterna-
tive” pathway requires activation of NF-κB–
inducing kinase (NIK) (4), which, in association 
with IKKα, binds to the C terminus of p100 
(also termed IκBδ), leading to p100 processing 
to p52 and the preferential release of p52:RelB 
dimers (5, 6). Although genetic studies have re-
vealed overlapping contributions of Rel family 
members in infl   ammation, proliferation, and 
cell survival, they have also identifi  ed distinct 
functions for individual family members with 
the alternative NF-κB pathway components 
being particularly important for secondary lym-
phoid tissue development and propagation of 
adaptive immune responses (7, 8). Importantly, 
excessive activity of either NF-κB activation 
pathway contributes to an array of human pat  h-
ologies, including cancer and infl  ammatory and 
autoimmune diseases (9–11).
Members of the TNF receptor (TNFR) 
  superfamily play vital roles in infl  ammatory 
  responses, lymphoid tissue development, and or-
chestration of adaptive immune responses via ac-
tivation of both the canonical and noncanonical 
NF-κB signaling pathways (1). The diverse bio-
logical eff  ects of TNFR family members are me-
diated, in part, via recruitment of one or more 
of a small family of cytoplasmic adaptor proteins 
called TNFR-associated factors (TRAFs) (12). 
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nonical NF-𝗋B activity. Importantly, TRAF3−/− B cells show ligand-independent up-regula-
tion of intracellular adhesion molecule 1 and protection from spontaneous apoptosis during 
in vitro culture. In addition, we demonstrate that loss of TRAF3 results in profound accu-
mulation of NF-𝗋B–inducing kinase in TRAF3−/− cells. Finally, we show that the early 
postnatal lethality observed in TRAF3-defi  cient mice is rescued by compound loss of the 
noncanonical NF-𝗋B p100 gene. Thus, these genetic data clearly demonstrate that TRAF3 
is a critical negative modulator of the noncanonical NF-𝗋B pathway and that constitutive 
activation of the noncanonical NF-𝗋B pathway causes the lethal phenotype of TRAF3-
defi  cient mice.
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TRAF proteins share a common C terminus, termed the TRAF-
domain, which mediates TRAF homo- and heterotrimerization 
as well as interaction with the receptor and downstream signal-
ing molecules. The N terminus of all known TRAFs (except 
TRAF1) contains several zinc-binding motifs that are believed 
to specify pathway activation potential. Although overexpres-
sion and genetic experiments have demonstrated the critical 
roles of TRAF2, -5, and -6 in activation of canonical NF-κB 
signaling, the mechanism by which TNFRs activate the nonca-
nonical pathway has remained elusive. Interestingly, the TNFR 
family members, lymphotoxin-β receptor (LTβR), B cell–
  activation factor receptor (BAFF-R), and CD40, all of which 
activate the noncanonical NF-κB pathway (5, 13, 14), also share 
the capacity to recruit the enigmatic adaptor molecule TRAF3 
(15–17). Recent studies have suggested that TRAF3 functions as 
a negative regulator of noncanonical NF-κB activation (18, 19). 
Clear genetic data defi  ning the function of TRAF3, however, 
has been lacking because of the early postnatal lethality associated 
with loss of TRAF3 signaling (20).
In this report, we demonstrate the essential role of 
TRAF3 in the negative regulation of noncanonical NF-κB 
activation as TRAF3 defi  ciency leads to constitutive p100 
processing caused by high NIK levels. The critical role of 
TRAF3 in suppression of noncanonical NF-κB activity is 
further illustrated by our fi  nding that constitutive p100 pro-
cessing is responsible for the lethal phenotype associated with 
TRAF3-null mice.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Loss of TRAF3 results in constitutive processing of p100
Analysis of LTβR-mediated signal transduction in mouse em-
bryonic fi  broblasts (MEFs) has provided a powerful system for 
the characterization of signaling components required for non-
canonical NF-κB activation (5). To gain insight into TRAF3’s 
role in the activation of the noncanonical NF-κB pathway, 
WT and TRAF3−/− MEFs were treated with agonistic anti-
LTβR antibody, and processing of the p100 precursor to p52, 
the hallmark of noncanonical NF-κB activation, was assessed 
by immunoblot. Although WT MEFs exhibited the normal 
kinetics of p100 processing with substantial p52 accumulation 
by 12 h after treatment, TRAF3−/− MEFs displayed constitu-
tive and total processing of the p100 precursor protein without 
stimulation (Fig. 1 A). To rule out the possibility that this ob-
servation was a developmental manifestation of TRAF3 defi  -
ciency rather than a direct eff  ect of TRAF3 on the noncanonical 
NF-κB pathway, WT TRAF3 was virally reconstituted into 
TRAF3−/− MEFs, and processing of p100 to p52 was again 
assessed by immunoblot. As seen in Fig. 1 B, reconstitution of 
WT TRAF3 restored WT levels of p100 and p52 in TRAF3−/− 
MEFs, indicating that the constitutive processing of p100 to 
p52 is caused by the loss of the TRAF3 gene.
TRAF3−/− B cells display multiple ligand-independent 
activation states
In addition to the central role of the noncanonical NF-κB 
pathway in LTβR orchestration of secondary lymphoid 
  tissues, noncanonical NF-κB activity also provides vital cues 
for B cells in several processes, including B cell development, 
peripheral maintenance, and antibody production (21, 22). 
Therefore, to better understand the function of TRAF3 in the 
inhibition of p100 processing, we examined cellular responses 
between WT and TRAF3−/− B cells. To obtain TRAF3−/− 
B cells, lethally irradiated C57BL/6 mice were reconstituted 
with fetal liver cells derived from WT or TRAF3−/− em-
bryos. 8 wk after reconstitution, spleens from reconstituted 
mice were harvested for B cell purifi  cation and analysis (the 
fi  delity of reconstitution and B cell purifi  cation was moni-
tored by tracking the donor allele, Ly9.1; Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20061166/DC1).
Initially, to determine whether TRAF3 was also required for 
suppression of p100 processing in B lymphocytes, WT and 
TRAF3−/− B cells were stimulated with agonistic anti-CD40 
antibody, BAFF, or LPS, and the processing of p100 to p52 
was assessed by immunoblot. As expected, ligation of either 
CD40 or BAFF-R, but not of TLR4, resulted in the process-
ing of p100 to p52 in WT B cells (Fig. 2 A). In TRAF3−/− 
B cells, however, generation of the p52 product occurred 
without stimulation (Fig. 2 A), again clearly defi  ning TRAF3 
as a negative regulator of noncanonical NF-κB activation. 
It is also noteworthy that although CD40 and LPS stimula-
tion of TRAF3−/− B cells resulted in substantial induction of 
Figure 1.  TRAF3 defi  ciency results in constitutive processing of 
p100 in MEFs. (A) WT and TRAF3−/− MEFs were stimulated with an anti-
LTβR antibody for the indicated times. Processing of p100 to p52 in whole 
cell extract was detected by immunoblot. Total β actin is shown as a load-
ing control. (B) Whole cell extracts from WT and TRAF3−/− MEFs reconsti-
tuted with either pBABEpuro-TAP or pBABEpuro-TAP-TRAF3 were assessed 
for basal p100 processing to p52 by immunoblot. Reconstitution of TRAF3 
expression in TRAF3−/− MEFs was confi  rmed by immunoblot. Total β actin 
is shown as a loading control. *, endogenous TRAF3.JEM VOL. 203, October 30, 2006  2415
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p100 protein, no further accumulation of p52 was observed 
in comparison with unstimulated TRAF3−/− cells. Similarly, 
BAFF- and CD40-stimulated WT cells exhibit similar levels 
of p52 production even though ligation of CD40 maintains 
high levels of p100, whereas ligation of BAFF-R does not. 
This suggests that loss of TRAF3 results in the maximal rate 
of p100 processing.
To further assess the biological signifi  cance of TRAF3 
defi  ciency, WT and TRAF3−/− B cells were cultured for 4 d 
in media alone or in the presence of either BAFF or agonistic 
anti-CD40 antibody, and viability was determined by prop-
idium iodide exclusion. Cultured B cells undergo spontane-
ous apoptosis unless provided with an appropriate survival 
signal, including such factors as CD40L or BAFF, the latter 
of which provides a vital survival signal for the maintenance 
of peripheral B cells in vivo (21). As shown in Fig. 2 B, 
TRAF3−/− B cells showed cell survival in the media control 
comparable with that seen in BAFF-treated WT cells. In ad-
dition to ligand-independent survival, TRAF3−/− B cells dis-
played high basal levels of intracellular adhesion molecule 
1 (ICAM-1) expression, similar to that seen in BAFF-stimu-
lated WT cells (Fig. 2 C), as well as the spontaneous forma-
tion of homotypic B cell aggregates (Fig. 2 D), a phenomenon 
that requires ICAM-1–LFA1 interaction (23). Previous 
  experiments indicated that certain B cell functions such as 
homotypic aggregation require both the canonical and 
  noncanonical NF-κB activity (24). Therefore, the pheno-
types of TRAF3−/− B cells described in this report may not 
be a sole consequence of constitutive noncanonical NF-κB 
activity. Although BAFF-R signaling is important for proper 
maintenance of B cell populations, excessive BAFF signaling 
also contributes to deleterious B cell responses by rescuing 
self-reactive B cells from peripheral deletion and promoting 
their entry into marginal zone niches, thereby increasing the 
opportunity for polyclonal stimulation and enhanced autoan-
tibody production (25). Consequently, it will be interesting 
to determine if mice carrying TRAF3−/− B cells develop 
  autoimmune phenotypes.
Loss of TRAF3 results in profound accumulation of NIK
A recent study examining the regulation of NIK protein levels 
demonstrated that inhibition of TRAF3 resulted in the 
marked accumulation of NIK, which suggests that TRAF3 
negatively regulates NIK stability (18). To test whether or not 
TRAF3 is required for suppression of NIK protein levels, 
  immunoblot analysis of NIK was performed on multiple 
TRAF3-defi  cient cell types, including immortalized B cells, 
3T3s, and MEFs. As shown in Fig. 3 A, in which NIK was 
undetectable in WT cells, profound accumulation of NIK was 
observed in all cells lacking TRAF3, which correlated well 
with increased processing of p100 to p52 (Fig. 3 A, bottom). 
Importantly, several groups have previously reported the dif-
fi  culty of detecting endogenous NIK (18, 26). To make cer-
tain this band was indeed NIK, NIK+/+ and NIK−/− 3T3s 
were treated with the proteosome inhibitor MG132 for 2 h to 
serve as a control (Fig. 3 A, right lanes). To verify that NIK 
was responsible for the constitutive processing of p100 ob-
served in TRAF3−/− cells, we performed siRNA-mediated 
knockdown of NIK in TRAF3−/− MEFs. As shown in Fig. 3 
B, TRAF3−/− MEFs treated with siRNA against NIK, but 
not with a scrambled control sequence, showed considerable 
reduction in NIK and p52 protein levels. Collectively, these 
fi  ndings indicate that TRAF3 indeed regulates activation of 
the noncanonical NF-κB pathway through inhibition of NIK 
protein levels.
At the present, it remains unclear how TRAF3 aff  ects 
NIK protein stability. Quantitative PCR analysis of NIK 
mRNA levels in MEFs and B cells demonstrated that loss of 
TRAF3 does not aff  ect transcription of NIK, which agrees 
with a published model that TRAF3 regulates NIK post-tran-
scriptionally (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20061166/DC1) (18). TRAF3 contains a 
zinc RING fi  nger motif characteristic of molecules with ubiq-
uitin ligase activity. In the Liao et al. study, the authors showed 
that direct interaction between NIK and TRAF3 was required 
for the suppressive function of TRAF3 toward NIK, suggest-
ing that TRAF3 may lead to the ubiquitination and degrada-
tion of NIK (18). In support of this, reconstitution of 
TRAF3−/− MEFs with a TRAF3 RING fi  nger point mutant 
showed defect in suppression of NIK protein levels (unpub-
lished data). However, we and other groups have been unable 
Figure 2.  TRAF3-defi  cient B lymphocytes display ligand-independent 
activation. (A) WT and TRAF3−/− B cells were stimulated with BAFF, anti-
CD40 antibody, or LPS for 24 h, and processing of p100 to p52 was detected 
by immunoblot. β actin is shown as a loading control. (B) WT and TRAF3−/− 
B cells were stimulated with BAFF or anti-CD40 antibody for 96 h, and cell 
death was measured by staining with propidium iodide. Error bars indicate 
±1 SD between duplicate samples. WT and TRAF3−/− B cells were stimu-
lated with BAFF for 48 h, and (C) analysis of ICAM-1 protein expression was 
determined by FACS and (D) images of cells forming homotypic aggregates 
were taken (see In vitro B cell assays for details).2416  RESCUE OF TRAF3-NULL MICE BY P100 NF-κB DEFICIENCY | He et al.
to see TRAF3-mediated ubiquitination of NIK in an overex-
pression assay (18). Moreover, TRAF proteins have only been 
shown to mediate lysine 63 ubiquitin linkages, which are not 
associated with protein degradation (27, 28) but rather the 
promotion of positive signaling complexes. To add to the 
complexity of noncanonical NF-κB activation, Grech et al. 
recently reported that loss of TRAF2 also results in constitu-
tive activation of the noncanonical NF-κB pathway (29). As 
such, in-depth studies are required to determine how TRAF2 
and TRAF3 are involved in controlling the levels of NIK be-
fore or after receiving signals from upstream receptors. Lessons 
learned from the characterization of the role of TRAF6-de-
pendent ubiquitination in activation of the canonical NF-κB 
pathway suggest that additional players remain to be identifi  ed 
to complete our understanding of TRAF-dependent suppres-
sion of NIK (28).
The TRAF3-null phenotype results from constitutive 
processing of p100
A previous study showed that constitutive activation of p52 
in mice lacking the C terminus of p100 (the IκBδ portion) 
leads to early lethality 3–5 wk after birth (30). Interestingly, 
TRAF3-defi  cient mice cannot survive beyond 2 wk of life 
(20). Therefore, we hypothesized that constitutive noncan-
onical NF-κB activity may have contributed to the TRAF3-
null phenotype. To investigate this possibility, we crossed 
TRAF3+/−/p100−/− mice in an attempt to generate double 
knockout animals. We found that loss of p100 rescued 
TRAF3−/− mice from postnatal lethality. Although TRAF3−/− 
mice die by postnatal day 12, TRAF3−/−/p100−/− mice grow 
at normal rates into adulthood (PCR and Western blot ana-
lyses were performed to confi  rm the TRAF3−/−/p100−/− 
genotype; Fig. 4, A and B; and not depicted). Interestingly, 
TRAF3−/− mice with one disrupted copy of the p100 gene 
could survive as long as 18 d (Fig. 4 B). Several abnormalities 
had previously been reported in TRAF3−/− mice, including 
drastically reduced spleen size and lymphocyte count, greatly 
reduced serum glucose levels, and elevated serum corticoste-
rone (20). As shown in Fig. 4 (C and D), all of these TRAF3−/− 
phenotypes are rescued with compound loss of the p100 gene. 
Collectively, these data demonstrate that constitutive activa-
tion of the noncanonical NF-κB pathway is an essential con-
tributor to the TRAF3-null phenotype.
Eff  orts to defi  ne the physiological role of TRAF3 began 
more than 10 yr ago. Unlike other TRAF family members, 
overexpression of TRAF3 did not result in the activation 
of the NF-κB pathway. As TRAF3-null mice died soon 
  after birth, identifi  cation of the function of TRAF3 had 
  remained a mystery. In this report, we provide genetic data 
that TRAF3 functions as a critical negative regulator of the 
noncanonical NF-κB pathway through inhibition of NIK 
protein levels. With our improved understanding of the 
Figure 3.  Enhanced NIK expression levels in TRAF3-defi  cient cells. 
(A) 150 μg of whole cell extracts from v-ABL–transformed WT and TRAF3−/− 
B cells, 3T3s, and primary MEFs were assessed by immunoblotting for 
NIK. p100 processing to p52 in these cells was confi  rmed by immunoblot. 
*, NIK+/+ and NIK−/− 3T3s were treated with MG132 for 2 h to serve as a 
control. (B) WT and TRAF3−/− MEFs were transfected with 150 nM control 
or NIK-siRNA. Whole cell extracts were obtained 48 h after transfection, 
and NIK and p100/p52 levels were detected by immunoblot. β actin is 
shown as a loading control.
Figure 4.  Rescue of TRAF3-null phenotypes by combined deletion 
of the p100 gene. The rescue of the TRAF3-null phenotype was exam-
ined by body size (A), survival (B), spleen size and total splenocyte count 
(C; error bars indicate ±1 SD between three mice), and serum glucose 
and corticosterone concentration (D; error bars indicate ±1 SD between 
two and fi  ve mice).JEM VOL. 203, October 30, 2006  2417
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  bifurcation of the NF-κB signaling pathways, we are now 
able to reassess the role of TRAF3 function in B lympho-
cytes. Our fi  nding that TRAF3−/− B cells receive a de facto 
BAFF signal suggests that TRAF3 plays an important role in 
the inhibition of inappropriate B cell activity and, therefore, 
may play a pivotal role in the suppression of B cell–mediated 
autoimmune disease. Most strikingly, we demonstrate that 
the lethal phenotype caused by TRAF3 defi  ciency results 
from constitutive processing of p100. Ultimately, the gener-
ation of a tissue-specifi  c strategy in the targeted disruption of 
TRAF3 may be required to defi  ne the mechanism of the 
early postnatal lethality that comes with loss of TRAF3. It is 
also worth noting that mice lacking the C-terminal IκBδ 
portion of p100 (30), which has constitutively activated p52, 
survive as long as 5 wk, suggesting that the exacerbated phe-
notype of TRAF3−/− mice may result from deregulation of 
additional pathways.
MATERIALS AND METHODS
Mice colony. C57BL/6 (The Jackson Laboratory) mice aged 6–12 wk 
were used as recipients in fetal liver transplant experiments. Targeted disrup-
tion of the TRAF3 allele and the p100 allele has been described previously 
(20, 24). The TRAF3 mice colony is maintained by mating TRAF3+/− 
mice, which are in a mixed C57BL/6-129 background. All mice were main-
tained and bred under specifi  c pathogen-free conditions in the University of 
California, Los Angeles Life Sciences mouse facility, and experiments were 
conducted within the parameters of our approved protocol by the Animal 
Research Committee.
Antibodies and reagents. The anti-p100/p52 and anti-NIK antibodies 
were purchased from Cell Signaling Technology, the anti-TRAF3 (M-20) 
antibody was purchased from Santa Cruz Biotechnology, Inc., and the anti-
LTβR antibody was purchased from Qbiogene. The anti–β actin antibody, 
propidium iodide, and LPS were obtained from Sigma-Aldrich.
Fetal liver reconstitution. Fetal livers were isolated from E14.5–15.5 em-
bryos in a mixed C57BL/6-129 background. After genotyping, TRAF3+/+ 
and  TRAF3−/− fetal livers were disrupted by passing cells through an 
18-gauge needle multiple times. After fi  ltration with a 70-μM cell strainer, 106 
cells were injected intravenously into irradiated C57BL/6 mice. 4–6 wk after 
reconstitution, cells from the blood of recipient mice were genotyped and ana-
lyzed by FACS for the presence of the Ly9.1 marker, which is expressed on 
the C57BL/6-129 donor cells but not on the C57BL/6 recipient cells.
B cell purifi  cation and transformation. Splenocytes were harvested from 
fetal liver–reconstituted mice 6–8 wk after reconstitution. To obtain pure naive 
B cells, total splenocytes were stained with a biotin-conjugated anti-CD43 an-
tibody (BD Biosciences), followed by streptavidin-conjugated magnetic micro-
beads (Miltenyi Biotec), and passed through a depletion-type magnetic sorting 
column (Miltenyi Biotec). Unbound cells were collected as the purifi  ed naive 
B cell sample and analyzed by FACS for Ly9.1, B220, and IgM markers. B cells 
from the reconstituted mice were retrovirally transformed using v-ABL.
Cell culture condition. B cells were cultured in RPMI medium 1640 
supplemented with 10% FBS, 50 μM β-mercaptoethanol, 100 U/ml peni-
cillin and 100 μg/ml streptomycin (Life Technologies) at 37°C under 10% 
CO2. MEFs isolated from E14.5–15.5 embryos were cultured in DMEM 
(Mediatech Inc.), supplemented with 5% fetal bovine serum, 100 U/ml 
penicillin, and 100 μg/ml streptomycin. TRAF3-null MEFs were infected 
with the Moloney murine leukemia virus ΨA-MLV, containing either 
the pBABEpuro-tandem affi   nity purifi  cation tag (TAP) or pBABEpuro-
TAP-TRAF3 vector, and selected with 2.5 μg/ml puromycin.
In vitro B cell assays. Purifi  ed splenic B cells were stimulated with 15 μg/ml 
anti-CD40 mAb (FgK-45), 5 μg/ml LPS, or 100 ng/ml human BAFF 
  (Amgen Biologicals). For the B cell survival assay, 2 × 105 B cells were stim-
ulated for 96 h in a fl  atbottom 96-well plate, and cell death was measured 
  after staining with propidium iodide and analyzed using a fl  ow cytometer 
(FACScan; Becton Dickinson). In the homotypic aggregation assay, cells 
were cultured in a fl  atbottom 96-well microtiter plate at 5 × 106 cells/ml for 
48 h, and cell images were taken using a microscope (Eclipse TE300; Nikon) 
with a 10× objective.
Measurement of serum glucose and corticosterone levels. Sera were 
isolated from 8-d-old mice. The glucose level was determined by applying 
serum to a one-touch strip and measured with a glucometer (Active; ACCU-
CHEK). The corticosterone amount was determined by using the Cortico-
sterone Immunoassay kit (R&D Systems).
Online supplemental material. Fig. S1 shows FACScan fl  ow cytometry 
analysis of B cell markers B220 and IgM and the C57BL/6-129 donor cell 
marker Ly9.1 on purifi  ed WT and TRAF3−/− B cells from fetal liver–reconsti-
tuted mice. Fig. S2 shows the basal levels of NIK mRNA in WT and TRAF3−/− 
MEFs and v-ABL–transformed B cells. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20061166/DC1.
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